These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 23640975

  • 21. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
    Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS.
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740
    [Abstract] [Full Text] [Related]

  • 22. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
    Cirone P, Andresen CJ, Eswaraka JR, Lappin PB, Bagi CM.
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):525-38. PubMed ID: 24442130
    [Abstract] [Full Text] [Related]

  • 23. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Zumsteg ZS, Morse N, Krigsfeld G, Gupta G, Higginson DS, Lee NY, Morris L, Ganly I, Shiao SL, Powell SN, Chung CH, Scaltriti M, Baselga J.
    Clin Cancer Res; 2016 Apr 15; 22(8):2009-19. PubMed ID: 26589432
    [Abstract] [Full Text] [Related]

  • 24. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
    Marquard FE, Jücker M.
    Biochem Pharmacol; 2020 Feb 15; 172():113729. PubMed ID: 31785230
    [Abstract] [Full Text] [Related]

  • 25. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
    Bhattacharya B, Akram M, Balasubramanian I, Tam KK, Koh KX, Yee MQ, Soong R.
    Cancer Biol Ther; 2012 Jan 01; 13(1):34-42. PubMed ID: 22336586
    [Abstract] [Full Text] [Related]

  • 26. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
    Zou Y, Ge M, Wang X.
    Biochem Biophys Res Commun; 2017 Aug 19; 490(2):385-392. PubMed ID: 28623128
    [Abstract] [Full Text] [Related]

  • 27. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
    Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S, Dahler A, Hazar-Rethinam M, de Long LM, Wooley K, Guminski A, Saunders NA.
    Br J Cancer; 2012 Jan 03; 106(1):107-15. PubMed ID: 22116303
    [Abstract] [Full Text] [Related]

  • 28. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
    Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O'Brien C, Spoerke JM, Patel S, Lensun L, Kassees R, Ross L, Lackner MR, Sampath D, Belvin M, Friedman LS.
    Mol Cancer Ther; 2011 Dec 03; 10(12):2426-36. PubMed ID: 21998291
    [Abstract] [Full Text] [Related]

  • 29. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
    Li KW, Wang SH, Wei X, Hou YZ, Li ZH.
    Eur Rev Med Pharmacol Sci; 2020 Dec 03; 24(24):12655-12666. PubMed ID: 33378012
    [Abstract] [Full Text] [Related]

  • 30. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
    Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA.
    Mol Cancer Ther; 2011 Aug 03; 10(8):1440-9. PubMed ID: 21632463
    [Abstract] [Full Text] [Related]

  • 31. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.
    Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, Penson T, Schmidt SP, Wojtkiewicz GR, Ning J, Subramanian M, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.
    Clin Cancer Res; 2019 Jun 01; 25(11):3374-3383. PubMed ID: 30796030
    [Abstract] [Full Text] [Related]

  • 32. PTEN deficiency contributes to the development and progression of head and neck cancer.
    Squarize CH, Castilho RM, Abrahao AC, Molinolo A, Lingen MW, Gutkind JS.
    Neoplasia; 2013 May 01; 15(5):461-71. PubMed ID: 23633918
    [Abstract] [Full Text] [Related]

  • 33. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
    Hsin IL, Shen HP, Chang HY, Ko JL, Wang PH.
    Cells; 2021 Oct 27; 10(11):. PubMed ID: 34831139
    [Abstract] [Full Text] [Related]

  • 34. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
    Friedman J, Nottingham L, Duggal P, Pernas FG, Yan B, Yang XP, Chen Z, Van Waes C.
    Clin Cancer Res; 2007 Nov 15; 13(22 Pt 1):6568-78. PubMed ID: 18006756
    [Abstract] [Full Text] [Related]

  • 35. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer.
    Izumi H, Wang Z, Goto Y, Ando T, Wu X, Zhang X, Li H, Johnson DE, Grandis JR, Gutkind JS.
    Mol Cancer Ther; 2020 Jul 15; 19(7):1562-1571. PubMed ID: 32430488
    [Abstract] [Full Text] [Related]

  • 36. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, Mora JL, Nayyar N, Schmidt SP, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.
    Neuro Oncol; 2019 Nov 04; 21(11):1401-1411. PubMed ID: 31173106
    [Abstract] [Full Text] [Related]

  • 37. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ, Guerra-Librero A, Fernandez-Gil BI, Florido J, García-López S, Martinez-Ruiz L, Mendivil-Perez M, Soto-Mercado V, Acuña-Castroviejo D, Ortega-Arellano H, Carriel V, Diaz-Casado ME, Reiter RJ, Rusanova I, Nieto A, López LC, Escames G.
    J Pineal Res; 2018 Apr 04; 64(3):. PubMed ID: 29247557
    [Abstract] [Full Text] [Related]

  • 38. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
    Xie J, Li Q, Ding X, Gao Y.
    Cell Physiol Biochem; 2018 Apr 04; 46(2):676-686. PubMed ID: 29621758
    [Abstract] [Full Text] [Related]

  • 39. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T, Yamada T, Koenig MJ, Xu J, Okimoto T, Li F, Amann JM, Carbone DP.
    J Thorac Oncol; 2019 Jun 04; 14(6):1061-1076. PubMed ID: 30825612
    [Abstract] [Full Text] [Related]

  • 40. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ, Heo JH, Park JY, Jeong JY, Cho HJ, Park KS, Kim SH, Moon YW, Kim JS, An HJ.
    Gynecol Oncol; 2019 Apr 04; 153(1):135-148. PubMed ID: 30686552
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.